Tesamorelin TSM5 5mg*10vials

Tesamorelin TSM5 (5mg x 10 vials) is an upgraded, medium-potency modified growth hormone-releasing hormone (GHRH) analog research peptide. It is an enhanced mid-range product in the TSM series, comprehensively optimized from the basic version, TSM2. It retains the structurally modified molecular framework unique to Tesamorelin, maintaining excellent resistance to enzymatic degradation and stable endogenous GH/IGF-1 axis activation properties. It inherits the core advantage of targeting and regulating visceral and hepatic lipid metabolism, distinguishing it from ordinary Sermorelin. TSM5 uses a standard 5mg medium concentration and optimized molecular binding activity. Compared to low-dose TSM2, it significantly improves lipolysis efficiency, remodels adipose tissue more deeply, and more effectively improves endocrine metabolism, resulting in more significant and distinguishable experimental phenotypes. It is perfectly suited for medium-gradient lipid metabolism studies, medium-intensity visceral fat ablation, moderate fatty liver metabolic intervention, and synergistic validation of complex peptide metabolism. As a core mainstream upgrade product in the TSM series, it covers most mid-to-high-level preclinical research scenarios for obesity-related metabolic disorders and age-related lipodystrophy.

Product Functions and Research Value

In systematic laboratory studies, Tesamorelin TSM5 stably triggered high-amplitude physiological pulsatile growth hormone (GH) secretion and sustained upregulation of insulin-like growth factor-1 (IGF-1), effectively activating mitochondrial metabolic activity and deep fat catabolism pathways. Compared to the mild baseline effect of TSM2, TSM5 exhibits comprehensively enhanced core metabolic functions, significantly improving efficacy in targeted breakdown of abdominal visceral fat, clearance of hepatic lipid deposits, improvement of adipose tissue inflammation, and regulation of insulin sensitivity. It effectively reduces deep visceral fat reserves, improves abnormal hepatic lipid metabolism, reverses moderate fatty liver metabolic disorders, and simultaneously enhances the maintenance of moderate lean tissue and anti-aging endocrine repair effects. TSM5 follows a natural physiological rhythm activation mechanism, without inhibiting feedback or causing hormone desensitization, balancing safe intervention with significant experimental efficacy. It is an ideal choice for exploring medium-dose gradient mechanisms, modeling mid-term chronic metabolic remodeling, and validating the combined efficacy of peptides, providing highly discriminative and reproducible authoritative data for in-depth research on the intervention mechanisms targeting lipid metabolism and metabolic syndrome.

Core Product Advantages

1. TSM5 Intermediate Enhanced Iteration: An intermediate-level upgrade of TSM2, optimizing molecular target activity and pathway affinity. It retains 100% of Tesamorelin's unique lipid-targeting properties while significantly enhancing metabolic regulation intensity, bridging the gap between mild, low-dose basic research and high-intensity extreme interventions.

2. Enhanced Visceral and Liver Lipid Targeting: Building upon basic lipolysis targeting, it further enhances the activation efficiency of deep fat and liver metabolic pathways, resulting in more thorough visceral fat reduction and liver lipid clearance, resolving the issue of insignificant phenotypic differentiation in the low-dose version.

3. Stable Modified Molecular Performance: Mature optimized structural modifications ensure durable anti-degradation stability, achieving continuous and stable metabolic signal activation. It does not cause drastic hormonal fluctuations or endocrine imbalances, making it suitable for long-term, moderate-intensity chronic metabolic intervention studies.

4. 5mg Balanced Gold Medium-Acting Strength: The classic mainstream medium-acting strength in the TSM series, balancing experimental biosafety and significant efficacy. This product avoids the problems of insufficient metabolic improvement from low-dose formulations and excessive physiological burden from ultra-high-dose interventions, making it the preferred specification for most routine gradient experiments and studies of the synergistic effects of complex peptides. 5. Pharmaceutical-grade high purity: Utilizing aseptic vacuum freeze-drying technology to fully lock in peptide peak activity. Each batch undergoes rigorous HPLC purity testing and comes with a complete official Certificate of Account (COA). The 10-vial aseptic integrated packaging is suitable for medium-sized laboratory research, key metabolic projects in universities, and global bulk wholesale procurement.

Tesamorelin TSM5 5mg*10-vial pack is a medium-potency, advanced modified GHRH analog research peptide, the mid-range flagship product in the TSM series. Compared to the basic product, its activity and efficacy are comprehensively improved.